Highly Potent Active Pharmaceutical Ingredients Market by API (Biological, Chemical), Drugs (Branded, Generic), Manufacturing (In-House, Outsourcing or Contact-Based), Therapeutic Area (Diabetes, Cardiovascular, CNS, Oncology, Musculoskeletal Drugs) and Forecast 2017-2021

Highly Potent Active Pharmaceutical Ingredients Market by API (Biological, Chemical), Drugs (Branded, Generic), Manufacturing (In-House, Outsourcing or Contact-Based), Therapeutic Area (Diabetes, Cardiovascular, CNS, Oncology, Musculoskeletal Drugs) and Forecast 2017-2021

Highly potent active pharmaceutical ingredients (HPAPIs) represent a significant change in the way pharmaceutical innovators are using small molecules to deliver new patient therapies. The shift toward highly potent APIs has not only led to a pipeline of more effective medicines that require lower doses and lead to fewer side effects, but also to new manufacturing challenges. During the last decade, the demand for HPAPIs has grown rapidly, mainly as a result of advances in clinical pharmacology and oncology research. HPAPIs drug manufacturing, storage and packaging is subject to Current Good Manufacturing Process (cGMP) regulations enforced by the U.S. FDA, EMEA and other international regulatory agencies. Contract manufacturing of HPAPI has been preferred over captive production due to high degree of competition and reduced profitability, geographical advantage and cost-effectiveness.

The global highly potent active pharmaceutical ingredients market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the API (biological, chemical), drug (branded, generic), manufacturing (in-house, outsourcing or contact-based), therapeutic area (diabetes, cardiovascular, CNS, oncology, musculoskeletal drugs, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).

The global highly potent active pharmaceutical ingredients market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global highly potent active pharmaceutical ingredients market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global highly potent active pharmaceutical ingredients market and included in this report are Alkermes plc, Cambrex Corporation, Dr. Reddy’s Laboratories, Lonza Group, Novasep, Sandoz International GmbH, Pfizer, Inc., Sigma-Aldrich Co. LLC, and WuXi AppTec.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Highly Potent Active Pharmaceutical Ingredients Market

1. Highly Potent Active Pharmaceutical Ingredients
1.1. Biological
1.2. Chemical

2. Drug
2.1. Branded (Innovative) Prescription Drugs
2.2. Generic Prescription Drugs

3. Manufacturing
3.1. Contract or Outsourcing Manufacturing
3.2. Captive (In-House) Manufacturing

4. Therapeutic Application
4.1. Anti-diabetic Drugs
4.2. Cardiovascular Drugs
4.3. Central Nervous System Drugs
4.4. Musculoskeletal Drugs
4.5. Oncology Drugs
4.6. Others (Antibacterial, Antiviral, Antifungal)

5. Company Profiles
5.1. Alkermes plc.
5.2. Cambrex Corporation
5.3. Dr. Reddy’s Laboratories
5.4. Lonza Group
5.5. Novasep
5.6. Pfizer, Inc.
5.7. Sandoz International GmbH
5.8. Sigma-Aldrich Co. LLC.
5.9. WuXi AppTec

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*